Abstract
This study investigates the determinants of SARS-CoV-2 anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of the Pfizer-BioNTech (BNT162b2) or Oxford-AstraZeneca (ChAdOx1) vaccines. Analyzing a cohort of 8,866 vaccinated HCWs, we found that 98.9% were seropositive more than 14 days after their first dose. Quantitative antibody responses were significantly higher in individuals with prior SARS-CoV-2 infection and in those who received the Pfizer-BioNTech vaccine compared to the Oxford-AstraZeneca vaccine. Notably, a single dose in previously infected individuals elicited antibody levels comparable to a full two-dose regimen in infection-naive individuals.
Introduction
In the early stages of the global COVID-19 vaccination campaign, understanding the real-world performance of different vaccine platforms was a critical priority. While clinical trials established high efficacy, questions remained regarding the quantitative immune response across diverse populations, particularly those with "hybrid immunity" from prior natural infection. This study addresses these gaps by comparing the Pfizer-BioNTech mRNA vaccine and the Oxford-AstraZeneca viral vector vaccine using a standardized quantitative assay in a large healthcare worker cohort at Oxford University Hospitals.
Methodology
Participants and Data Collection
The researchers conducted a prospective cohort study utilizing data from the Infections in Oxfordshire Research Database. The study analyzed 8,866 vaccinated HCWs who participated in regular PCR and antibody testing. The dataset included longitudinal PCR results, pre-vaccination serology to identify prior asymptomatic infections, and post-vaccination quantitative measurements.
Laboratory Analysis
Antibody levels were measured using the Abbott SARS-CoV-2 IgG II Quant assay, which targets the spike receptor-binding domain (RBD). This assay provides a numerical value in Arbitrary Units per milliliter (AU/ml), with a detection threshold of ≥50 AU/ml, allowing for a more granular analysis than binary "positive/negative" results.
Statistical Modeling
Generalized Additive Models (GAMs) were employed to track antibody responses over time, accounting for variables such as age, vaccine type, and infection history. Multivariable logistic regression was used to identify predictors of seropositivity.
Results
Seroconversion Rates
Overall, 98.9% of HCWs tested seropositive more than 14 days after their first dose. Specifically:
- Pfizer-BioNTech: 99.5% (2706/2720) seropositivity.
- Oxford-AstraZeneca: 97.1% (864/890) seropositivity. All 470 HCWs tested after their second dose were seropositive.
Quantitative Antibody Titers
The magnitude of the antibody response varied significantly based on vaccine type and prior infection status:
- Pfizer-BioNTech: Median titers were 14,604 AU/ml in previously infected individuals versus 1,028 AU/ml in naive individuals.
- Oxford-AstraZeneca: Median titers were 10,095 AU/ml in previously infected individuals versus 435 AU/ml in naive individuals.
The Pfizer vaccine generally produced higher quantitative titers than the AstraZeneca vaccine after the first dose. Furthermore, the second dose of the Pfizer vaccine in naive individuals boosted titers to a median of 10,058 AU/ml, effectively matching the levels achieved by previously infected individuals after only one dose.
Determinants of Response
Age was a significant factor; younger HCWs generally showed more robust responses to the first dose. This age gradient was more pronounced among recipients of the Oxford-AstraZeneca vaccine. No significant differences in seropositivity were observed based on sex or ethnicity, although vaccine uptake was lower in lower-paid roles and certain minority ethnic groups.
Discussion
The findings underscore the powerful "priming" effect of natural infection. The synergy between prior infection and a single vaccine dose results in antibody levels equivalent to a full two-dose schedule in naive populations.
Policy Implications
These data suggest that in settings of vaccine scarcity, a single-dose strategy for individuals with confirmed prior infection could be an effective "vaccine-sparing" measure, allowing resources to be prioritized for those without existing immunity.
Limitations and Future Work
While the study provides robust quantitative data, several limitations remain. The specific antibody level required for total protection against infection (correlates of protection) remains undefined. Additionally, the cohort was limited to working-age adults (median age 39), and results may differ for elderly or pediatric populations. Finally, the study focused on IgG antibodies and did not measure T-cell responses or neutralization capacity against newer variants like Delta or Omicron.
Conclusion
Vaccination with either Pfizer-BioNTech or Oxford-AstraZeneca leads to detectable anti-spike antibodies in nearly all adult HCWs. While quantitative differences exist between vaccine types and based on prior infection status, both platforms are highly effective at inducing seroconversion. Whether these differences in quantitative response impact long-term vaccine efficacy requires further longitudinal study.
Summary updated